Cardiomyopathy Management.
Personalized, physician-led cardiomyopathy management with direct access to your cardiology team. Proactive monitoring. Faster interventions. Better outcomes.
Understanding cardiomyopathy management.
Cardiomyopathies — diseases of the heart muscle — represent a diverse group of conditions that collectively affect millions of Americans. Dilated cardiomyopathy (DCM) is the most common, affecting approximately 1 in 250-500 people and accounting for nearly half of all heart transplants. Hypertrophic cardiomyopathy (HCM) affects 1 in 500 people (approximately 660,000 Americans) and is the leading cause of sudden cardiac death in young athletes. Arrhythmogenic right ventricular cardiomyopathy (ARVC), restrictive cardiomyopathy, and cardiac amyloidosis round out the major subtypes, each with distinct management requirements. The 2024 AHA/ACC Hypertrophic Cardiomyopathy guidelines and the emergence of disease-modifying therapies — mavacamten for obstructive HCM, tafamidis for transthyretin cardiac amyloidosis — have transformed cardiomyopathy management from purely supportive care to targeted intervention. Cardiac MRI with late gadolinium enhancement has become essential for diagnosis, risk stratification, and monitoring, providing tissue characterization that echocardiography alone cannot offer. Our concierge cardiomyopathy program integrates advanced imaging, genetic testing and counseling, guideline-directed medical therapy, sudden death risk stratification, and family screening into a comprehensive management plan tailored to each patient's specific cardiomyopathy subtype.
Why concierge cardiology for this condition.
Cardiomyopathy management is among the most complex areas of cardiology. A patient with HCM needs regular sudden death risk assessment using the HCM Risk-SCD calculator, serial imaging to track wall thickness and outflow gradients, exercise restriction counseling, genetic testing with cascade screening of relatives, and — for obstructive disease — consideration of mavacamten, septal myectomy, or alcohol septal ablation. A patient with cardiac amyloidosis needs technetium pyrophosphate scanning for diagnosis, genetic testing for hereditary ATTR, and tafamidis therapy that costs over $200,000/year and requires insurance navigation. These are not conditions that can be managed in a 15-minute visit every six months. Concierge care provides 60-minute quarterly visits with cardiomyopathy-focused evaluation, cardiac MRI coordination and detailed interpretation with imaging specialists, genetic testing with pre- and post-test counseling, same-day access for new symptoms such as syncope, presyncope, or worsening dyspnea, and proactive family screening protocols that can detect disease in relatives before sudden death occurs.
What we monitor.
Our management approach.
Expected outcomes.
Related concierge services.
Get specialized concierge cardiomyopathy care with advanced imaging, genetic testing, and expert management.
Direct physician access, proactive monitoring, and personalized care plans. Concierge cardiology starting at $295/month.